Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.
about
Genome-wide analysis of small RNA and novel MicroRNA discovery in human acute lymphoblastic leukemia based on extensive sequencing approachTreatment including intrathecal chemotherapy with and without cranial irradiation for prevention of central nervous system relapse of childhood acute lymphoblastic leukemiaTreatment including intrathecal chemotherapy with and without cranial irradiation for prevention of central nervous system relapse of childhood acute lymphoblastic leukemiaAcute lymphoblastic leukaemiaTreating childhood acute lymphoblastic leukemia without cranial irradiationA PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology GroupProgress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology GroupMercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fictionOral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.Chemotherapy-related side effects in childhood acute lymphoblastic leukemia in Indonesia: parental perceptions.Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407Central nervous system disease in hematologic malignancies: historical perspective and practical applications.Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trialOutcomes for children and adolescents with cancer: challenges for the twenty-first century.Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report.Declining childhood and adolescent cancer mortalityDexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.BET inhibition as a single or combined therapeutic approach in primary paediatric B-precursor acute lymphoblastic leukaemia.Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group.Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology groupSignificant 25-hydroxyvitamin D deficiency in child and adolescent survivors of acute lymphoblastic leukemia: treatment with chemotherapy compared with allogeneic stem cell transplant.Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.Survivors of standard risk acute lymphoblastic leukemia do not have increased risk for overweight and obesity compared to non-cancer peers: a report from the Children's Oncology GroupRisk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.Detection of central nervous system leukemia in children with acute lymphoblastic leukemia by real-time polymerase chain reactionObesity in patients with acute lymphoblastic leukemia in childhoodGlucocorticoid use in acute lymphoblastic leukaemiaIntrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic lAntimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy.The impact of dexamethasone and prednisone on sleep in children with acute lymphoblastic leukemiaEffect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trialSystematic Review of the Toxicity of Long-Course Oral Corticosteroids in Children.
P2860
Q21142773-527986D5-4C60-45D4-8117-7BA0E4ABDB6FQ24197564-6074C265-8CA5-4BFB-93D5-B383262A6547Q24236240-47DC920D-A7D6-4C8C-8A42-65960960840CQ24602387-D6D183D3-36D8-4586-9CF5-DEA5E3C04CB4Q24644599-B80630F3-D3A4-42FA-8825-9AD6A43AAC78Q24656610-D48B8534-5C5F-4BF7-8EBC-837020053FF5Q24657000-2A5D4BA0-CE74-483D-B0C6-59D042E769D2Q27023839-B8BCF6E2-4F74-4AC8-8ABF-BC04EF3920C1Q33388076-DBA84946-D8F9-419A-9F86-3904148BA392Q33499635-6D7ADD2B-0DEE-471E-8D50-F4D73FE27E08Q33559419-509D8AEA-D5ED-4265-8B77-56ADC82F1B6CQ33585849-75D89C7E-98DA-4E3A-925D-1EDE9A432485Q33828580-A57D1F53-8FE3-4443-A3EE-95B01A5A4441Q33897659-A4CA917D-DA4E-4822-B9E3-5867D571E529Q33997207-9058D9CE-C9C7-4149-BDBB-988A30A007E0Q34003323-AB03094C-5145-445F-A9A5-83CB134A42CDQ34060045-AD33CDEC-9185-4C4B-9E20-4803E7CB0BDBQ34095614-FBF0C4E6-F1DF-4B38-B155-8894046B0DA4Q34358853-E01BF31B-5668-43DA-9386-2850F77FD7EEQ34530196-EF4ED5AD-BCB1-44B7-9FF1-FA1CBFE830B3Q34707213-75647506-7813-4E13-A8D7-847116FFCBA2Q34707586-DDA01E6C-6534-45F3-84EE-8C4EBF0B75D3Q34992080-E598D090-F9A7-42E5-85C3-F6134AE8EBB1Q35103530-ECAD0E80-9310-410A-8B2D-29B9E23DEB9CQ35112206-4138FBDB-3E5B-4551-9EFD-953DBFC3530AQ35513785-83805CE9-324F-4096-B887-64F9A23482D0Q35616078-361B553D-049F-467B-8A8E-A45F604EF30FQ35659879-03B25EFA-E5B5-4D82-9938-C27F6DEE84DAQ35667279-21E0F2B4-2E87-4851-A20C-D4A9EEFA1470Q35776973-BA706422-35BA-46FF-8F16-B315FE831378Q35781265-CB6880CA-D3B0-4869-8C89-91084F92F20BQ35789804-923B9745-528C-40D8-99A4-1485CCBCC0A8Q35809004-9297D097-CC65-40A9-B5BB-A730B51BC603Q35844745-5E29E0CE-BA66-4144-9208-CCD02BBD5833Q35849907-01805908-0877-429F-8B4A-4CBEAEBE26DCQ35925012-ABD7C2D4-7D05-4D4B-994D-427FCA21ED84Q35936879-E19A307D-8BB1-4B60-BB3A-D307370D63FFQ35997653-353D5302-D0A4-490F-8AAE-A2F735A3F7E6Q36251056-CB4CA4AA-629F-4ED5-8CA5-8958494B302AQ36261095-0FB45CAC-42ED-4DA5-89C0-F56F95E5D8B6
P2860
Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Dexamethasone versus prednison ...... m the Children's Cancer Group.
@en
Dexamethasone versus prednison ...... m the Children's Cancer Group.
@nl
type
label
Dexamethasone versus prednison ...... m the Children's Cancer Group.
@en
Dexamethasone versus prednison ...... m the Children's Cancer Group.
@nl
prefLabel
Dexamethasone versus prednison ...... m the Children's Cancer Group.
@en
Dexamethasone versus prednison ...... m the Children's Cancer Group.
@nl
P2093
P921
P1433
P1476
Dexamethasone versus prednison ...... m the Children's Cancer Group.
@en
P2093
Arthur J Provisor
Bruce C Bostrom
Children's Cancer Group
Gary R Erdmann
Harland N Sather
Katherine Johnston
Martha R Sensel
Michael E Trigg
Raymond J Hutchinson
P304
P356
10.1182/BLOOD-2002-08-2454
P407
P577
2003-01-16T00:00:00Z